Sean Hall
Medlab Clinical LTD, Australia
Title: Potentiating new neurological pain drugs from cannabis (CBD/THC)
Biography
Biography: Sean Hall
Abstract
Neurology is a complex area, potentially requiring a combination of surgical and non-surgical intervention. Regardless of the intervention plan, neurology is hindered with a number of co-morbidities that can diminish patient outcomes, one in particular is pain. Pain management requires a number of pharmaceutical agents principally from the opioid class of drugs, potentiating heightened secondary organ toxicity profiles. Further it is accepted that some 33% + of patients undergoing chemotherapy will state that their pain is under-managed. Cannabinoids potentiate new treatments in pain management and posit opioid reduction. Theoretically, the argument appears sound; in real world practice, cannabinoid preparations differ vastly ultimately affecting the efficacy of the final product. This presentation will take a first-hand look at Medlab’s work into developing a standardised and validated “early” drug used in clinical trial and suited for Regulatory (TGA, FDA, EMA) acceptance.